Catheter Precision, Inc.

Medical Devices • Healthcare • Fort Mill, SC, United States • VTAK (ASE)

973 691 2000 1670 Highway 160 West, Fort Mill, SC 29708, United States

Quarter: Q4 2025 Reported: October 15, 2025 Sentiment: Neutral

Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.

Analysis Summary

This 8-K filing reports on the outcomes of Catheter Precision, Inc.'s (VTAK) Special Meeting of stockholders held on October 10, 2025, and is not an earnings call transcript. Therefore, financial performance metrics, detailed business segment analysis, and forward guidance on operations are not available.

The meeting saw 641,616 shares represented, constituting approximately 43.1% of the 1,487,266 outstanding shares. All three proposed matters received shareholder approval.

**Detailed Analysis of Proposals:**
1. **Increase in Authorized Common Stock (Proposal No. 1):** Shareholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from sixty (60) million to five hundred (500) million shares. This proposal passed with 497,162 votes For, 133,882 Against, and 10,571 Abstentions. This substantial increase provides the company with significant headroom for future equity financing, stock-based compensation plans, mergers and acquisitions, or other corporate purposes without requiring further shareholder approval for each issuance. While offering strategic flexibility, it also introduces the potential for significant dilution to existing shareholders if a large number of new shares are issued.
2. **Ratification of Accounting Firm (Proposal No. 2):** The appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2026, was ratified. This proposal passed overwhelmingly with 610,134 votes For, 16,778 Against, and 14,703 Abstentions. This is a routine but important corporate governance matter, ensuring continuity in financial auditing and compliance.
3. **Adjournment/Postponement of Meeting (Proposal No. 3):** Shareholders approved the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos 1 and/or 2. This proposal passed with 514,362 votes For, 120,394 Against, and 6,860 Abstentions. This provides procedural flexibility, though it ultimately wasn't needed as all primary proposals passed.

**Management Commentary and Forward Guidance:**
As this is an 8-K filing reporting on stockholder votes, there is no management commentary or forward guidance on business operations, financial performance, or market trends typically found in an earnings call transcript. The approval of the share increase, however, implicitly suggests management anticipates future needs for capital or shares for strategic purposes.

**Competitive Positioning and Market Trends:**
This document does not provide information on competitive positioning or market trends.

**Risk Factors and Concerns:**
The primary risk stemming from this meeting is the potential for significant dilution of existing shareholder value due to the massive increase in authorized shares. While providing flexibility, the lack of specific stated purpose for immediate issuance could create uncertainty. The relatively low voter turnout (43.1%) might also be a minor concern regarding overall shareholder engagement.

**Analyst Q&A Highlights:**
There was no analyst Q&A as this was a report on a special stockholder meeting, not an earnings call.

Key Highlights

• Shareholders approved increasing authorized common stock from 60 million to 500 million shares.
• This significant increase provides the company with substantial flexibility for future capital raises or strategic initiatives.
• All three proposals presented at the Special Meeting passed with clear majorities.
• WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for fiscal year 2026.
• Approximately 43.1% of outstanding shares were represented at the meeting.

Financial Metrics

eps

YoY: N/A

revenue

N/A

YoY: N/A

guidance

net income

N/A

YoY: N/A

Stock Performance (90 Days)

Data through Dec 26, 2025

Layoff Events

Earnings Calls

Positive Signals

• Shareholder approval of a substantial increase in authorized common stock provides significant capital raising and strategic flexibility.
• All management-backed proposals passed with clear majorities, indicating shareholder support.
• Ratification of the independent auditor ensures continued strong corporate governance and compliance.
• The company successfully held its Special Meeting and obtained necessary approvals for future strategic options.

Risks & Concerns

— Significant potential for future shareholder dilution due to the large increase in authorized common stock.
— Uncertainty regarding the specific timing, purpose, and terms of any future issuance of the newly authorized shares.
— Relatively low shareholder participation (43.1% of outstanding shares represented) at the Special Meeting.